SCHEMBL3882201

SCHEMBL3882201

CC(C)Oc1ccc(CCC(=O)O)cc1-c1ccc2ccccc2c1

nearest known ligand 0.64

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 7/20 0.64
S1PR5 Q9H228 9/20 0.51
S1PR1 P21453 8/20 0.51
S1PR3 Q99500 7/20 0.51
CYP1A2 P05177 1/20 0.48
FFAR1 O14842 2/20 0.47
CCNC P24863 1/20 0.47
CDK8 P49336 1/20 0.47
TP53 P04637 1/20 0.46
MDM2 Q00987 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3884730 0.89 CCNC (0.53) FFAR4S1PR5S1PR1S1PR3CYP1A2
SCHEMBL3683148 0.87 FFAR4 (0.61) FFAR4CYP1A2FFAR1CCNCCDK8
SCHEMBL3882947 0.84 FFAR4 (0.80) FFAR4CYP1A2FFAR1CCNCCDK8
SCHEMBL3883021 0.84 S1PR5 (0.46) FFAR4S1PR5S1PR1S1PR3
SCHEMBL3884456 0.82 FFAR1 (0.60) FFAR4FFAR1
SCHEMBL3882571 0.82 FFAR4 (0.51) FFAR4S1PR5S1PR1S1PR3FFAR1
SCHEMBL3885554 0.82 FFAR4 (0.56) FFAR4CYP1A2FFAR1CCNCCDK8
SCHEMBL3887901 0.81 FFAR4 (0.58) FFAR4CYP1A2FFAR1CCNCCDK8
SCHEMBL3683679 0.79 FFAR4 (0.60) FFAR4CYP1A2FFAR1CCNCCDK8
SCHEMBL3679192 0.79 FFAR4 (0.58) FFAR4S1PR1CYP1A2FFAR1CCNC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1477472-B1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2009-01-14 EP claimed
CN-100387576-C Substituted phenylalkanoic acid derivatives and use thereof ASAHI CHEMICAL IND (JP) 2008-05-14 CN claimed
CN-1653032-A Substituted phenylalkanoic acid derivatives and use thereof ASAHI CHEMICAL IND (JP) 2005-08-10 CN claimed
US-6867320-B2 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2005-03-15 US claimed
EP-1477472-A1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2004-11-17 EP claimed
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2004-03-04 US claimed
EP-1477472-B1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2009-01-14 EP disclosed
CN-100387576-C Substituted phenylalkanoic acid derivatives and use thereof ASAHI CHEMICAL IND (JP) 2008-05-14 CN disclosed
CN-1653032-A Substituted phenylalkanoic acid derivatives and use thereof ASAHI CHEMICAL IND (JP) 2005-08-10 CN disclosed
US-6867320-B2 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2005-03-15 US disclosed
EP-1477472-A1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2004-11-17 EP disclosed
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2004-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof PTGER1, CYSLTR1, PTGS1 FFAR4 115/4885S1PR5 202/4885S1PR1 77/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.